Alan Pollack

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610
    Larry Pan
    Department of Radiation Oncology, Prince Edward Island Cancer Treatment Centre, Charlottetown, PEI, Canada
    Radiat Oncol 8:100. 2013
  2. pmc The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02
    Alan Pollack
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin Cancer Res 15:5478-84. 2009
  3. pmc MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02
    Li Yan Khor
    Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Suite 1501, Miami, FL 33130, USA
    J Clin Oncol 27:3177-84. 2009
  4. pmc Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202
    Arnab Chakravarti
    Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
    J Clin Oncol 25:3082-9. 2007
  5. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
  6. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
  7. pmc Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
    Radka Stoyanova
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:1151-60. 2007
  8. pmc A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
  9. pmc Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer
    Niraj Pahlajani
    Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
    Int J Radiat Oncol Biol Phys 82:1949-56. 2012
  10. ncbi request reprint Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005

Research Grants

Detail Information

Publications82

  1. pmc Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610
    Larry Pan
    Department of Radiation Oncology, Prince Edward Island Cancer Treatment Centre, Charlottetown, PEI, Canada
    Radiat Oncol 8:100. 2013
    ..The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate cancer...
  2. pmc The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02
    Alan Pollack
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin Cancer Res 15:5478-84. 2009
    ..Here, we attempt to verify our prior findings and test the hypothesis that the relationship of the length of AD to patient outcome is affected by PKA(RIalpha) overexpression...
  3. pmc MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02
    Li Yan Khor
    Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Suite 1501, Miami, FL 33130, USA
    J Clin Oncol 27:3177-84. 2009
    ..CONCLUSION Combined MDM2 and Ki-67 expression levels were independently related to distant metastasis and mortality and, if validated, could be considered for risk stratification of patients with prostate cancer in clinical trials...
  4. pmc Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202
    Arnab Chakravarti
    Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
    J Clin Oncol 25:3082-9. 2007
    ..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
  5. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ....
  6. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
    ..However, there is little direct evidence that dose escalation has an impact on distant metastasis (DM) or overall mortality (OM). These associations were examined in the current study...
  7. pmc Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
    Radka Stoyanova
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:1151-60. 2007
    ..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
  8. pmc A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
    ..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
  9. pmc Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer
    Niraj Pahlajani
    Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
    Int J Radiat Oncol Biol Phys 82:1949-56. 2012
    ..However, local failure is also a major problem. We sought to establish the importance of more aggressive local radiotherapy (RT) to ≥80 Gy...
  10. ncbi request reprint Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
    ..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
  11. ncbi request reprint Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 62:397-405. 2005
    ..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
  12. ncbi request reprint Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 70:67-74. 2008
    ..To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer...
  13. ncbi request reprint The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  14. pmc What dose of external-beam radiation is high enough for prostate cancer?
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:682-9. 2007
    ..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
  15. ncbi request reprint Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..To determine whether the radiation dose is a determinant of clinical outcome in patients with a lymph node risk of >15% treated using whole pelvic (WP), partial pelvic (PP), or prostate only (PO) fields...
  16. ncbi request reprint What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:1003-10. 2005
    ..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
  17. ncbi request reprint Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  18. ncbi request reprint Hazards of dose escalation in prostate cancer radiotherapy
    Deborah Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:1260-8. 2003
    ..To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications...
  19. pmc Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 68:599-609. 2008
    ..In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells...
  20. ncbi request reprint Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation
    Steven J Feigenberg
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 8:2268. 2007
    ..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
  21. ncbi request reprint Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 69:79-87. 2007
    ..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
  22. pmc Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  23. pmc Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  24. doi request reprint Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer
    Navesh K Sharma
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 80:437-44. 2011
    ..The present study compared the genitourinary and gastrointestinal (GI) toxicity in men treated with 3D-CRT+AD vs. IMRT+AD...
  25. pmc Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 71:1309-15. 2008
    ....
  26. pmc Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 13:3585-90. 2007
    ..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
  27. pmc How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 70:1487-91. 2008
    ..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
  28. pmc Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  29. ncbi request reprint Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
    ..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
  30. ncbi request reprint A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 59:380-5. 2004
    ..Two models for stratification of prostate cancer aggressiveness predominate for the purposes of daily treatment decision making. This study investigates the relationships between these two clinically popular models...
  31. ncbi request reprint Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs
    Lili Chen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:903-11. 2007
    ....
  32. ncbi request reprint Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:43-52. 2004
    ....
  33. ncbi request reprint Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The temporal kinetics of posttreatment PSA levels was examined to define the error in the classification of BF...
  34. pmc Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer
    Alan Pollack
    Alan Pollack, Gail Walker, and Radka Stoyanova, University of Miami Miller School of Medicine, Miami, FL Eric M Horwitz, Robert Price, Richard E Greenberg, Robert G Uzzo, Charlie Ma, and Mark K Buyyounouski, Fox Chase Cancer Center, Philadelphia, PA Steven Feigenberg, University of Maryland, Baltimore, MD Andre A Konski, Wayne State University Medical Center and Benjamin Movsas, Henry Ford Hospital, Detroit, MI
    J Clin Oncol 31:3860-8. 2013
    ..To determine if escalated radiation dose using hypofractionation significantly reduces biochemical and/or clinical disease failure (BCDF) in men treated primarily for prostate cancer...
  35. ncbi request reprint A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 29:458-62. 2006
    ..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
  36. doi request reprint Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 79:1310-7. 2011
    ..To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer...
  37. ncbi request reprint Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 68:1417-23. 2007
    ..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
  38. doi request reprint Gains from real-time tracking of prostate motion during external beam radiation therapy
    Jin sheng Li
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 75:1613-20. 2009
    ..To study the gains from real-time tracking of prostate motion and threshold-based intervention and the feasibility of margin reduction for external beam radiation therapy of prostate cancer...
  39. ncbi request reprint Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA
    J Clin Oncol 25:3603-8. 2007
    ..The specific aim of this study was to examine the cost effectiveness of proton beam radiation compared with current state-of-the art therapy in the treatment of patients with prostate cancer. Materials and..
  40. ncbi request reprint Does age matter in the selection of treatment for men with early-stage prostate cancer?
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 106:2598-602. 2006
    ....
  41. ncbi request reprint Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 169:2153-7; discussion 2157-9. 2003
    ..We evaluated the impact of backdating on no biochemical evidence of disease (bNED) control and suggest changes in the definition...
  42. ncbi request reprint Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Khanh H Nguyen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:377-83. 2003
    ....
  43. ncbi request reprint Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II
    Jeff M Michalski
    Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 56:192-8. 2003
    ..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
  44. ncbi request reprint Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 60:187-96. 2004
    ..In this study, we tested whether interruption of MDM2 function using antisense MDM2 oligonucleotide (AS) affects the apoptotic response of prostate cancer cells to AD...
  45. doi request reprint The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms
    Radka Stoyanova
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Cancer 119:1080-8. 2013
    ..The authors designed a model to estimate the results of various doses of radiotherapy (RT) combined with various durations of ADT...
  46. doi request reprint MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Phys Med Biol 57:535-45. 2012
    ....
  47. ncbi request reprint MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT
    Lili Chen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 60:636-47. 2004
    ..Furthermore, it will reduce treatment cost by avoiding redundant CT scans and save patient, staff, and machine time. The purpose of this study is to investigate the dosimetric accuracy of MRI-based treatment planning for prostate IMRT...
  48. ncbi request reprint Experience of ultrasound-based daily prostate localization
    Anurag Chandra
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:436-47. 2003
    ....
  49. doi request reprint Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 71:938-41. 2008
    ..The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer...
  50. pmc Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 109:2011-5. 2007
    ..This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy...
  51. pmc Does treatment duration affect outcome after radiotherapy for prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 72:1402-7. 2008
    ..In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer...
  52. pmc Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 66:25-30. 2006
    ..In this study we examined bcl-2 and bax expression as predictive markers in men treated with radiotherapy +/- androgen deprivation on Radiation Therapy Oncology Group (RTOG) protocol 86-10...
  53. ncbi request reprint Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:59-66. 2008
    ..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
  54. ncbi request reprint Target localization for post-prostatectomy patients using CT and ultrasound image guidance
    Kamen Paskalev
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 6:40-9. 2005
    ..However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements...
  55. ncbi request reprint Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 54:677-85. 2002
    ..These issues were investigated in a cohort of men with Stage T1-T3 prostate cancer who were randomized to receive between 70 Gy and 78 Gy and were prospectively biopsied at about 2 years after the completion of radiotherapy (RT)...
  56. ncbi request reprint The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 112:55-60. 2008
    ..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
  57. ncbi request reprint Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003
    ..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
  58. ncbi request reprint Positive prostate biopsy laterality and implications for staging
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 62:298-303. 2003
    ..Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used...
  59. doi request reprint Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo
    Thirupandiyur S Udayakumar
    Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
    Int J Radiat Oncol Biol Phys 79:549-58. 2011
    ..Here, we demonstrate the radiosensitization efficacy of adenovirus (Ad)-E2F1 infection in growing (orthotopic) LNCaP and (subcutaneous) PC3 nude mice xenograft tumors...
  60. ncbi request reprint The Gleason score shift: score four and seven years ago
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 56:1241-7. 2003
    ..There is some evidence that Gleason scores (GS) have shifted over time, although documentation of the extent to which this has occurred and its clinical significance is sparse...
  61. ncbi request reprint Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Nat Clin Pract Oncol 2:12-3. 2005
  62. ncbi request reprint Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 58:743-9. 2004
    ..This is the first description of the ability to limit the dose received by the penile bulb (PB) and corporal bodies (CB) using intensity-modulated radiotherapy (IMRT)...
  63. ncbi request reprint MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:962-7. 2005
    ....
  64. ncbi request reprint Influence of number of CAG repeats on local control in the RTOG 86-10 protocol
    May Abdel-Wahab
    Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
    Am J Clin Oncol 29:14-20. 2006
    ..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)...
  65. ncbi request reprint Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study
    Darren J Little
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Urology 62:707-13. 2003
    ..To assess patient-reported prostate cancer-specific quality of life 2 and 3 years after radiotherapy to the prostate in a randomized dose-escalation trial of 70 versus 78 Gy conducted from 1993 to 1998...
  66. pmc Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
    Pino Alcantara
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 109:41-7. 2007
    ..0001).CONCLUSIONS.nPSA12 is a strong independent predictor of outcome after RT alone for prostate cancer and should be useful in identifying patients at high risk for progression to metastasis and death...
  67. ncbi request reprint Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
    ....
  68. ncbi request reprint Parameters for treatment decisions for salvage radiation therapy
    Shelly Bowers Hayes
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 23:8204-11. 2005
    ..These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone...
  69. ncbi request reprint Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:634-9. 2002
    ..To investigate whether low partial pressure of oxygen (PO2) in prostate cancer (CaP) predicts for biochemical outcome after radiotherapy. We previously reported that hypoxic regions exist in human CaP...
  70. ncbi request reprint Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 97:1630-8. 2003
    ..The current study examined the association between expression levels of Ki-67, bcl-2, bax, and bcl-x in pretreatment biopsy specimens and patient outcome after definitive radiotherapy alone...
  71. ncbi request reprint Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
    Alan Pollack
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 53:1097-105. 2002
    ..A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer...
  72. ncbi request reprint Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:22-30; discussion 30-1. 2002
    ..The results with long-term ADT are much more convincing than short-term ADT, and, as a consequence, 2 to 3 years are recommended...
  73. ncbi request reprint Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    World J Urol 21:200-8. 2003
    ..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
  74. pmc Antisense Bcl-2 sensitizes prostate cancer cells to radiation
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 65:331-40. 2005
    ..The relationship of Bcl-2 expression in four prostate cancer cell lines, and the effect of modulating expression with a Bcl-2 antisense oligonucleotide (G3139, Genasense, oblimersen sodium, Genta Incorporated), to RT was examined...
  75. ncbi request reprint Treatment of prostate cancer with regional lymph node (N1) metastasis
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 13:121-9. 2003
    ..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
  76. ncbi request reprint Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:336-43. 2004
    ..Because AD + radiation (RT) is a key strategy for the treatment of men with high-risk prostate cancer, AS was tested for the ability to sensitize cells to the combination of AD+RT...
  77. ncbi request reprint Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 54:1314-21. 2002
    ..To identify dosimetric, anatomic, and clinical factors that correlate with late rectal toxicity after three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer...
  78. doi request reprint Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:671-7. 2008
  79. ncbi request reprint Postprostatectomy radiation therapy for prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 18:15-22. 2008
    ..Because the morbidity of postoperative radiotherapy is relatively low, when pathologic high risk factors are present adjuvant radiotherapy should be considered. The role of androgen deprivation postprostatectomy is less well defined...
  80. ncbi request reprint Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 66:408-15. 2006
    ....
  81. ncbi request reprint A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate
    Robert A Price
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:843-52. 2003
    ..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
  82. pmc Predictive models in external beam radiotherapy for clinically localized prostate cancer
    Mack Roach
    Department of Radiation Oncology, University of California at San Francisco, San Francisco, California, USA
    Cancer 115:3112-20. 2009
    ..Cancer 2009;115(13 suppl):3112-20. (c) 2009 American Cancer Society...

Research Grants5

  1. Radiation, Hormones & Antisense Prostate Cancer Therapy
    Alan Pollack; Fiscal Year: 2007
    ..abstract_text> ..